From Plastic Bottles to Parkinson's Treatment: A New Path for Waste

A research team at the University of Edinburgh has developed a method to convert common plastic waste into levodopa, a primary medication for Parkinson's disease. The study, published in Nature Sustainability, uses engineered bacteria for the conversion and is presented as a potential sustainable alternative to current production methods, though significant scaling challenges remain.

The Process: Engineering Bacteria to Transform Waste

Scientists engineered E. coli bacteria to convert the chemical components of polyethylene terephthalate (PET) plastic into levodopa. PET is a ubiquitous plastic found in items like drink bottles and food packaging. The process harnesses the carbon atoms embedded within the plastic's chemical structure as a building block for the drug.

This method is positioned as an alternative to conventional levodopa production, which the researchers describe as relying on fossil fuel-based chemical steps and being energy-intensive.

Building on a Foundation of Previous Research

This breakthrough builds directly on earlier work by the same team, which demonstrated that PET plastic could be converted into the common pain reliever paracetamol. That prior process was reported to convert up to 90% of the plastic from a one-liter bottle within 24 hours.

This development is part of a growing field exploring plastic waste as a feedstock for valuable pharmaceuticals:

• In 2022, University of Southern California researchers showed engineered fungi could break down polyethylene (PE) plastic into compounds useful for making antibiotics and other drugs.
• A separate collaborative study led by the University of St Andrews demonstrated PET could be converted into starting materials for cancer therapies and drugs used to control bleeding.

Potential Impact and Significance

Parkinson's disease affects over 10 million people globally, and levodopa is widely considered the most effective treatment for managing its symptoms, such as tremors and muscle stiffness.

The research suggests that converting plastic waste into medicines could serve a dual purpose: reducing reliance on fossil fuels for pharmaceutical production and supporting the principles of a circular economy, where waste materials are repurposed into new, valuable products.

Challenges on the Path to Application

The researchers are clear that several major hurdles must be overcome before this laboratory process can be implemented practically:

• Scaling and Cost: The process must be scaled up to industrial production, requiring the development of cost-effective manufacturing methods.
• Regulatory Approval: Any pharmaceutical product derived from this method must undergo rigorous testing to meet established safety and efficacy standards set by health regulators.
• Feedstock Collection: Sourcing sufficient quantities of clean, sorted plastic waste for production is noted as a logistical challenge, as it would compete with traditional fossil fuel feedstocks used by the chemical industry.

The study concludes that advancing this promising technology will require sustained, long-term investment and collaboration between scientists, industry, and policymakers.